|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
11,270,000 |
Market
Cap: |
290.65(M) |
Last
Volume: |
197,427 |
Avg
Vol: |
196,888 |
52
Week Range: |
$13.82 - $26.5 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
5,250 |
117,800 |
Total Buy Value |
$0 |
$0 |
$74,754 |
$2,088,813 |
Total People Bought |
0 |
0 |
2 |
3 |
Total Buy Transactions |
0 |
0 |
5 |
21 |
Total Shares Sold |
0 |
0 |
0 |
27,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Varian John |
CEO |
|
2015-01-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
377,184 |
|
- |
|
Baker Julian |
Director |
|
2015-01-06 |
4 |
S |
$3.86 |
$3,860,000 |
I/I |
(1,000,000) |
345,074 |
|
- |
|
Baker Julian |
Director |
|
2015-01-05 |
4 |
S |
$3.81 |
$3,824,078 |
I/I |
(1,003,300) |
366,515 |
|
- |
|
Baker Julian |
Director |
|
2015-01-02 |
4 |
S |
$3.55 |
$753,740 |
I/I |
(212,100) |
388,063 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2015-01-02 |
4 |
AS |
$3.55 |
$17,756 |
D/D |
(5,000) |
81,346 |
|
- |
|
Klein Thomas |
Chief Commercial Officer |
|
2014-12-31 |
5 |
A |
$3.83 |
$11,498 |
I/I |
3,001 |
4,660 |
|
- |
|
Neal James R |
VP Business Development |
|
2014-12-31 |
5 |
A |
$3.83 |
$11,498 |
I/I |
3,001 |
4,471 |
|
- |
|
Neal James R |
VP Business Development |
|
2014-12-31 |
5 |
A |
$3.41 |
$2,585 |
D/D |
758 |
140,988 |
|
- |
|
Scannon Patrick J Md Phd |
Exec. VP & CSO |
|
2014-12-31 |
5 |
A |
$3.83 |
$11,498 |
I/I |
3,001 |
25,080 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-12-31 |
5 |
A |
$3.83 |
$6,019 |
I/I |
1,571 |
6,881 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-12-31 |
5 |
A |
$3.41 |
$2,057 |
D/D |
603 |
77,498 |
|
- |
|
Varian John |
CEO |
|
2014-12-31 |
5 |
A |
$3.83 |
$11,498 |
I/I |
3,001 |
18,538 |
|
- |
|
Kurland Fred |
CFO & VP Finance |
|
2014-12-31 |
5 |
A |
$3.83 |
$11,498 |
I/I |
3,001 |
22,137 |
|
- |
|
Baker Julian |
Director |
|
2014-12-30 |
4 |
S |
$3.65 |
$1,430,239 |
I/I |
(391,900) |
392,617 |
|
- |
|
Baker Julian |
Director |
|
2014-12-29 |
4 |
S |
$3.68 |
$812,440 |
I/I |
(221,000) |
401,032 |
|
- |
|
Baker Julian |
Director |
|
2014-12-26 |
4 |
S |
$3.71 |
$486,460 |
I/I |
(131,100) |
405,778 |
|
- |
|
Baker Julian |
Director |
|
2014-12-19 |
4 |
S |
$4.21 |
$3,168,580 |
I/I |
(752,900) |
408,603 |
|
- |
|
Baker Julian |
Director |
|
2014-12-18 |
4 |
S |
$4.29 |
$710,687 |
I/I |
(165,700) |
424,785 |
|
- |
|
Baker Julian |
Director |
|
2014-12-17 |
4 |
S |
$4.31 |
$2,958,129 |
I/I |
(686,500) |
428,343 |
|
- |
|
Baker Julian |
Director |
|
2014-12-16 |
4 |
S |
$4.27 |
$1,363,271 |
I/I |
(319,200) |
443,096 |
|
- |
|
Baker Julian |
Director |
|
2014-12-15 |
4 |
S |
$4.45 |
$2,050,652 |
I/I |
(460,800) |
449,970 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-12-15 |
4 |
AS |
$4.63 |
$7,401 |
D/D |
(1,600) |
72,021 |
|
- |
|
Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
|
2014-12-15 |
4 |
OE |
$3.04 |
$4,864 |
D/D |
1,600 |
73,621 |
|
- |
|
Varian John |
CEO |
|
2014-12-15 |
4 |
AS |
$4.49 |
$44,929 |
D/D |
(10,000) |
367,184 |
|
- |
|
Varian John |
CEO |
|
2014-12-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
377,184 |
|
- |
|
354 Records found
|
|
Page 11 of 15 |
|
|